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The Economic Impact of Biotechnology in New England  
Executive Summary 
 
New England’s biotechnology industry is comprised of about 1,134 businesses, which 
employ a total of 94,107 workers.  These establishments generated $21.0 billion in sales in 
2002, which provided $7.2 billion in wages and salaries.  When multiplier effects (i.e., 
indirect impacts) are included, the biotechnology industry contributed about $35.7 billion in 
output to the New England region.  Through direct and indirect impacts on their respective 
state economies, the biotechnology establishments support a total of 221,390 jobs, which 
paid $13.0 billion in wages and salaries to workers across New England.   
 
Measured by economic output, the New England biotechnology industry is dominated by 
manufacturers of pharmaceutical and diagnostics substances, and scientific and analytical 
instruments.  Establishments that primarily conduct research and development in the life 
sciences are an important sub-sector in terms of employment.  Massachusetts has the largest 
and most diversified biotechnology industry in New England, while Vermont and Rhode 
Island have the smallest industries in the region. 
 
Boston’s early development as a leading center of biotechnology in the United States 
appears to have influenced the growth of the biotechnology industry in New England.  Four 
counties in the Boston area account for nearly 60 percent of all biotechnology 
establishments in New England.  Generally speaking, the number of biotechnology 
establishments located in a county diminishes as the distance from Boston increases.  
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Exceptions to this trend include two counties in southwestern Connecticut, which are part of 
a New York – Long Island cluster, and single counties in Maine and New Hampshire that 
have minor clusters of biotechnology establishments (i.e., ten or more establishments).   
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The Economic Impact of Biotechnology in New England 
 
1. INTRODUCTION 
Scientific discoveries in biotechnology hold the promise of new products and medical 
treatments, better ways to make existing goods and services, and the birth of entirely new 
industries.  To some observers, the potential economic and other impacts from 
commercialization of biotechnologies are only now beginning to emerge.  While the actual 
direction and ultimate magnitude of biotechnology-related growth is still unclear, many 
states have implemented economic development strategies intended to support the evolution 
of this industry as a source of employment and income growth.  As of 2001, 41 U.S. states 
had programs in place that specifically target the biotechnology industry (Battelle et al, 
2001). 
 
A recent industry study found that biotechnology-related firms in the United States, not 
counting the large multinational pharmaceutical companies, employed 150,000 workers and 
generated $20 billion in sales in 1999 (Morrison and Giovannetti, 1999).  The study also 
found that biotechnology-related output in the United States more than doubled between 
1993 and 1999.  The New England region hosts a major center of biotechnology activity.  
The Boston CMSA (Consolidated Metropolitan Statistical Area) is one of the two leading 
centers of biotechnology in the United States, out of 51 CMSAs with a population of one 
million or more people (Cortwright and Mayer, 2002).  Included in the Boston CMSA are 
portions of Massachusetts, New Hampshire, Maine and Connecticut.   
 
 5 
This study investigates the economic impacts of biotechnology on the New England region.  
We consider the impacts of biotechnology on the region as a whole, as well as the impacts 
on individual New England states.  The analysis is based on secondary data sources, 
including government statistics, publicly available on-line sources and written publications, 
and proprietary industry directories.  This study is part of a larger project that examined 
aspects of the Maine biotechnology industry.  Two companion reports, published in 
December of 2002 and November of 2003, focused on the economic impact of the Maine 
biotechnology industry and the business climate for biotechnology in Maine.   
 
2. NEW ENGLAND’S BIOTECHNOLOGY FIRMS 
Biotechnology is defined as “any technique that uses living organisms or parts of organisms 
to make or modify products, to improve plants or animals, or to develop microorganisms for 
specific uses” (Busch et al., 1991).  This classifies biotechnology in terms of a process (i.e., 
use of living organisms) rather than in terms of an identifiable final product.  Since 
industrial classification systems (e.g., Standard Industrial Classification System, North 
American Industrial Classification System) are generally based on the final product or 
service associated with a business, biotechnology firms are not classified within a single 
industry in published government statistics.   
 
Previous studies have combined a variety of industrial categories in the Standard Industry 
Classification (SIC) system, and the more recent North American Industry Classification 
System (NAICS), as a way to collect secondary data on the biotechnology industry 
(Morrison and Giovannetti, 1999; Peters, 2000; Cortwright and Mayer, 2002).  With this 
approach, the definition of the “biotechnology industry” can be broadened or narrowed by 
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increasing or decreasing the number and breadth of industrial sectors included in the 
analysis.  For example, a study with a narrow definition of the biotechnology industry might 
be restricted to a small number of industrial categories such as “in-vitro diagnostic 
substances” (NAICS 325413), “biological products, except diagnostic” (NAICS 325414), 
and “research and development in the life sciences” (NAICS 5417102).  A study that takes a 
broad view of the industry could add pharmaceutical manufacturers, makers of medicinal 
and botanical products, and firms that produce specialized instruments, chemicals or 
equipment utilized by the biotechnology, medical or health care industries.  
 
A weakness of this general approach lies in the nature of biotechnology as a process that 
may or may not be employed at the firm level, regardless of its inclusion in a specific 
industrial category.  As mentioned above, the SIC and NAICS classifications are product- 
(or service-) based and do not necessarily reflect the technologies used by firms.  This study 
attempts to overcome this limitation through the use of biotechnology business directories as 
a key source of information to identify entities (e.g., businesses, laboratories, non-profit 
organizations) that use biotechnology in New England.  We make the assumption, with 
some exceptions, that inclusion in a biotechnology directory identifies an entity as a 
“biotechnology firm” without regard to its associated SIC of NAICS category.  Throughout 
this report, the terms biotechnology “firm,” “business,” and “establishment” are used 
interchangeably to include businesses, as well as research laboratories and institutions. 
 
The study relies primarily on three electronic listings of biotechnology firms: BioZak 
InfoBase, Bio-Link and Informagen.  BioZak InfoBase is a proprietary subscription service 
that provides firm-level data, including employment, revenue and other information 
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organized by state and by biotechnology sub-sector.  Bio-Link is a National Science 
Foundation funded project that is used to link biotechnology-related educators, 
organizations and businesses.  It provides a freely accessible listing, by state, of 
biotechnology firm names and addresses.  Informagen is a private corporation that provides 
bioinformatics tools, databases and consulting services to the biotechnology industry.  It 
also publishes an on-line database of biotechnology company names and addresses.   
 
The list of firms assembled from the three biotechnology directories was carefully reviewed 
to remove entries that did not appear to be biotechnology firms.  These included entities 
such as direct health care providers, universities, and industry associations that were 
determined to be outside the scope of this study.  When necessary and appropriate, we 
supplemented the information collected in the industry directories with data from other 
secondary sources, including County Business Patterns and databases contained within the 
IMPLAN input-output modeling software.  For example, in cases where the industry 
directories did not provide employment data, we used County Business Patterns data to 
estimate an establishment’s employment level. 
 
We acknowledge some potential weaknesses in our approach.  First, the biotechnology 
directories rely heavily on information that is self-reported by businesses.  This may result 
in the inclusion of businesses that do not use biotechnology, and possibly the omission of 
firms that choose not to submit information or relevant entities that are not identified by the 
developers of the database.  As indicated above, care was taken to remove firms from the 
database that did not fit within our definition of the biotechnology industry.  Therefore, we 
believe that the issue of self-reporting in the databases is not significant problem.  Second, it 
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is not evident how frequently the data are updated.  Thus, the databases may include entities 
that are no longer in operation.  However, it is possible that the firms included in the 
databases that no longer exist may offset some of the relevant biotechnology firms that are 
not listed in the databases.  Finally, it appears that, in some cases, the employment and 
revenue data listed in the directories refer to the total national or international operations of 
a firm and not those of a single establishment.  We made efforts to identify those records 
and consulted business websites and other data sources when employment figures listed in 
the directories seemed unrealistically high. 
 
3. STUDY FINDINGS 
The analysis presented in this report is based on 1,134 biotechnology establishments that we 
identified in the New England states of Connecticut, Maine, Massachusetts, New 
Hampshire, Rhode Island and Vermont.  These establishments employed an estimated 
96,306 workers and produced $21.4 billion in output in 2002.   
 
Figure 1 shows the number of biotechnology firms, by county, across the New England 
region.  Four counties in the Boston metropolitan area (Suffolk, Norfolk, Middlesex and 
Worcester) have a combined total of 668 biotechnology establishments, which is about 60 
percent of the industry’s establishments in New England.  Along with San Francisco, the 
Boston metropolitan area was one of the earliest centers of research in biotechnology.  
Supported by a concentration of large universities and an established venture capital 
industry, the Boston-based biotechnology industry has continued to grow and remains one 
of the dominant biotechnology centers in the country (Cortwright and Mayer, 2002).   
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Figure 1.  Biotechnology firms in New England. 
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It is evident that there has been some expansion of biotechnology activity outward from the 
Boston center, but that it has not progressed much beyond the counties located nearest to the 
city (Hillsborough and Rockingham counties in New Hampshire; Essex, Plymouth and 
Bristol counties in Massachusetts; Providence county in Rhode Island).  The exception 
appears to be a cluster of biotechnology firms located in southwestern Connecticut (Fairfield 
and New Haven counties near the core of the cluster, and Hartford, Middlesex and 
Litchfield counties at the periphery).  These firms are part of a major biotechnology cluster 
that is centered in New York and Long Island.  Other areas in the region with ten or more 
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biotechnology establishments include Cumberland County in Maine and Grafton County in 
New Hampshire. 
 
3.1 BIOTECHNOLOGY ACTIVITY BY INDUSTRY SUB-SECTOR 
In this study, we separate the biotechnology industry into seven sub-sectors, described in 
detail in appendix A.  Although many biotechnology firms could be counted in multiple 
categories, we used the information provided in the biotechnology directories to assign each 
establishment to a single sub-sector in order to avoid double-counting.  The largest sub-
sector, measured in terms of the number of business establishments, includes businesses that 
manufacture scientific and analytic instruments for use in the biotechnology industry (table 
1).  This sub-sector is also the largest in terms of employment, with 39,217 workers in New 
England.   
 
Table 1.  Sub-sectors of the biotechnology industry in New England. 
 
          Industry Sub-sector Establishments Employment 
Output 
($000s) 
Agricultural & marine biotechnology  20   126  $11,272.8 
Pharmaceutical & diagnostic substances  189   23,595  $  9,480,719.2 
Wholesale trade  141   7,490   $ 1,246,226.8 
Scientific & analytical instruments  376   37,017   $ 7,591,452.6 
Information & data processing  47   5,190   $ 732,001.6 
Medical & diagnostic labs  52   803  $ 49,792.8 
Research & development in life sciences  308   19,885  $ 1,849,745.5 
  Total  1,134   94,107  $ 20,961,211.3  
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The sub-sector comprised of businesses engaged primarily in research and development in 
the life sciences is the second largest, in terms of numbers of businesses, with 308 
establishments.  Since these research 
and development-intensive firms are 
relatively small in terms of 
employment size, this sub-sector 
ranks third in total employment 
behind “scientific and analytic 
instruments” and “pharmaceutical 
and diagnostic substances”.   
 
In terms of economic output, the 
largest sub-sector of biotechnology in 
New England includes businesses that 
produce pharmaceutical and 
diagnostic substances (figure 2).  This 
sub-sector, with the highest average 
output per worker, generates nearly 
$9.5 billion of output annually.  
Businesses involved in the production 
of scientific and analytical 
instruments used in biotechnology 
contribute the second highest level of 
Figure 2.  Output by sub-sector. 
Figure 3.  Employment by sub-sector. 
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output among the seven sub-sectors of biotechnology.  Research and development-oriented 
businesses and organizations are focused on the discovery and/or development of new 
knowledge, new products and new biotechnologies.  With less emphasis on the marketing 
and sales of products, biotechnology firms that focus primarily on research and development 
produce considerably less output than businesses involved in the production of 
pharmaceutical and diagnostic substances or scientific and analytical instruments. 
 
As a result of differences in output per worker across some of the biotechnology 
sub-sectors, the distribution of output differs from that of workers (figure 3).  
Pharmaceutical and medicine manufacturing, with a high output per worker, accounts for 
45.2 percent of total industry output in New England, but only 25.1 percent of total industry 
employment.  Conversely, firms that are primarily engaged in research and development 
have a lower output per worker.  Therefore, this sub-sector accounts for only 8.8 percent of 
industry output in New England with 25.1 percent of the industry’s workers.  Shares of 
output and employment are more comparable in the remaining industry sub-sectors. 
 
With the large concentration of biotechnology firms in the Boston region, it is not surprising 
that Massachusetts has the largest share of New England’s biotechnology industry.  The 
state accounts for 65 percent of the region’s biotechnology employment and 60 percent of 
the industry’s output.  The second largest state for biotechnology, Connecticut, has slightly 
more than 30 percent of the region’s biotechnology output.  The other four New England 
states, as a group, have less than 10 percent of the industry’s output (Figure 4) and only 12.6 
percent of the industry’s employment.  
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The distribution of industry output and employment across the six New England states 
varies for each biotechnology sub-sector.  With its long coastline and large fisheries, Maine 
produces 60 percent of the output in the area of marine and agricultural biotechnology, 
which equates to approximately $6.8 million.  According to the industry directories used in 
the study, Massachusetts is the only other state in New England with activity in marine and 
agricultural biotechnology.  The production of pharmaceutical and diagnostic substances is 
heavily dominated by firms in Massachusetts and Connecticut.  These states each produce 
about 47 percent of the region’s output of pharmaceutical and diagnostic substances, while 
the remaining four New England states, as a group, produce only 5 percent of regional 
output in this sub-sector of biotechnology. 
Figure 4.  Shares of biotechnology industry output in New England, by state. 
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Massachusetts dominates production in the other five biotechnology sub-sectors.  The 
state’s share of output ranges from 62 percent of New England’s production in scientific and 
analytical instruments to 86 percent of the region’s output in life sciences research and 
development.  While Connecticut has the second largest share of biotechnology output in 
most industry sub-sectors, it has a surprisingly small proportion of activity in life sciences 
research and development.  In that sub-sector, Maine follows Massachusetts with 6 percent 
of regional output, while Connecticut contributes 5 percent of New England’s output in life 
sciences research and development.  However, it is likely that Connecticut’s large 
pharmaceutical companies engage in substantial research and development activities to 
support the development of drugs and diagnostic substances. 
Figure 5.  Biotechnology sub-sector output, by state. 
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3.2 ECONOMIC IMPACT OF BIOTECHNOLOGY 
As indicated above, the biotechnology industry in New England consists of 1,134 
establishments, which employed an estimated 96,306 workers and produced $21.4 billion 
with of output in 2002.  Industry sales, included in the $21.4 billion in output, supported an 
estimated $7.3 billion of wages, salaries and profits paid to biotechnology employees and 
business owners.  Along with the output and employment directly associated with the 
industry, biotechnology businesses located in New England impact the region and state 
economies through the purchases made from other businesses, as well as the personal 
expenditures made by their employees.  These indirect impacts, commonly referred to as an 
industry’s “multiplier effect”, are estimated using a state-level input-output (i.e., IMPLAN) 
model for each the New England states. 
 
When the multiplier effects are included, the total economic contribution of the industry to 
the economies of the New England states is $36.4 billion (table 2). Through direct and 
indirect impacts on their respective state economies, the biotechnology establishments 
support a total of 226,034 jobs in New England that provide $13.2 billion of income. 
 
Table 2.  Economic impacts of the biotechnology industry in New England (2002). 
 
Direct 
impacts 
Multiplier  
effects Total impact 
    
  Output ($000s) $ 20,961,211.3 $14,777,031.2 $  35,738,242.5 
    
  Income ($000s) $  7,215,011.7 $ 5,812,388.1 $ 13,027,399.8 
    
  Employment 94,107 127,283 221,390 
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4. STATE BIOTECHNOLOGY PROFILES 
This section presents a brief overview of the biotechnology industry in each of the New 
England states.  We discuss several key aspects of the biotechnology industry in each state, 
including the number of establishments, employment and output in the various industry 
sub-sectors.  Finally, we present information on the economic contribution of the 
biotechnology industry in each state, including the direct and indirect contributions of the 
industry to output, employment and income. 
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4.1 BIOTECHNOLOGY IN CONNECTICUT 
 Connecticut’s biotechnology industry consists of 136 establishments.  These 
businesses produced $6,514.8 million in output, paid $1,965.3 million in wages and 
salaries, and employed 21,569 workers in 2002.  When multiplier effects are 
included, the industry contributed $11,218.0 million in output to the Connecticut 
economy, provided $3,774.3 million in personal income, and supported 58,073 jobs. 
 The state is home to several large pharmaceutical companies, including four 
international corporations that have major research operations in the state.  
Companies that manufacture pharmaceutical products and medicines account for 68 
percent of the direct output, and over one-half of the workers employed in 
Connecticut’s biotechnology industry. 
 Connecticut has a large number of businesses that manufacture scientific and 
analytical instruments, and organizations that conduct biotechnology-related 
research and development.  However, these sub-sectors are much smaller than 
Connecticut’s pharmaceutical companies in terms of total employment and output. 
 
Table 3.  Economic impact of the Connecticut biotechnology industry. 
 
Direct 
impacts 
Multiplier  
effects Total impact 
    
  Output ($000s) $ 6,514,834.3  $ 4,703,152.0 $ 11,217,986.3 
    
  Income ($000s) $  1,965,272.5 $ 1,808,980.1 $ 3,774,252.6 
    
  Employment 21,569 36,504 58,073 
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Table 4.  Sub-sector employment and output in Connecticut’s biotechnology industry. 
          Industry Sub-sector Establishments Employment 
Output 
($000s) 
Agricultural & marine biotechnology * * * 
Pharmaceutical & diagnostic substances  20   10,408   $4,460,253.6 
Wholesale trade  14   1,228   $202,012.8  
Scientific & analytical instruments  63   7,846   $1,642,123.5  
Information & data processing  8   808   $104,810.8  
Medical & diagnostic labs  4   94   $5,908.7  
Research & development in life sciences  28   1,186   $99,725.0  
  Total  136   21,569   $6,514,834.3  
*Data withheld; category includes 3 or fewer establishments. 
 
 
 
 
Figure 6.  Output in Connecticut’s biotechnology industry. 
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Figure 7.  Employment in Connecticut’s biotechnology industry. 
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4.2 BIOTECHNOLOGY IN MAINE 
 The Maine biotechnology industry consists of 80 establishments.  These businesses 
produced $432.3 million in output, paid $135.6 million in wages and salaries, and 
employed 3,690 workers in 2002.  When multiplier effects are included, the industry 
contributed $685.0 million in output to the Maine economy, provided $228.1 million 
in personal income, and supported 7,135 Maine jobs. 
 The two largest sub-sectors of biotechnology in Maine include businesses that 
manufacture pharmaceutical products and medicines, and organizations that conduct 
biotechnology-related research and development.  Each of these sub-sectors is 
dominated by a single large establishment with numerous smaller ones. 
 Maine’s biotechnology industry is highly concentrated in the southern part of the 
state.  About 50 percent of biotechnology establishments and 59 percent of 
biotechnology-related jobs are located in Cumberland and York counties (Allen and 
Gabe, 2002). 
 
Table 5.  Economic impact of the Maine biotechnology industry. 
 
Direct 
impacts 
Multiplier  
effects Total impact 
    
  Output ($000s) $432,278.0  $252,751.0  $685,029.0 
    
  Income ($000s) $135,588.0  $92,502.0  $228,090.0 
    
  Employment  3,690   3,445  7,135 
 
 21 
 
Table 6.  Sub-sector employment and output in Maine’s biotechnology industry. 
          Industry Sub-sector Establishments Employment 
Output 
($000s) 
Agricultural & marine biotechnology * * * 
Pharmaceutical & diagnostic substances  25   1,176  $ 206,211.0 
Wholesale trade  4   22  $ 6,414.4 
Scientific & analytical instruments  11   666  $ 98,338.0 
Information & data processing * * * 
Medical & diagnostic labs  4   25  $ 4,082.5 
Research & development in life sciences  25   1,727  $ 110,416,000 
  Total  80   3,689  $ 432,278.2 
*Data withheld; category includes 3 or fewer establishments. 
  
Figure 8.  Output in Maine’s biotechnology industry. 
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Figure 9.  Employment in Maine’s biotechnology industry. 
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4.3 BIOTECHNOLOGY IN MASSACHUSETTS 
 
 The biotechnology industry in Massachusetts consists of 776 establishments.  These 
businesses produced $12,768.6 million in output, paid $4,799.0 million in wages and 
salaries, and employed 62,476 workers in 2002.  When multiplier effects are 
included, the industry contributed $22,001.3 million in output to the state economy, 
provided $8,514.6 million in personal income, and supported 142,835 jobs. 
 Massachusetts’ biotechnology industry is the largest and most diversified among the 
New England states.  Overall, it accounts for approximately one-third of all 
establishments, output, personal income, and employment associated with 
biotechnology in New England. 
 The state’s dominant position in New England biotechnology is likely due to the 
early establishment of the Boston area as one of the country’s major biotechnology 
centers.  Fueled by a strong infrastructure for research and the commercialization of 
new discoveries, the Massachusetts biotechnology industry has achieved a critical 
mass of activity necessary to create the positive dynamics of industry clustering.  As 
evidence, the value of recent biotechnology research alliances in the Boston region is 
the highest in the country and more than double that of the next highest region 
(Cortwright and Mayer, 2002). 
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Table 7.  Economic impact of the Massachusetts biotechnology industry. 
 
Direct 
impacts 
Multiplier  
effects Total impact 
    
  Output ($000s) $ 12,768,610.4  $ 9,232,693.5 $ 22,001,303.9 
    
  Income ($000s) $ 4,798,962.3 $ 3,715,633.0 $ 8,514,595.2 
    
  Employment 62,476 80,359 142,835 
 
 
 
Table 8.  Sub-sector employment and output in Massachusetts’ biotechnology industry. 
          Industry Sub-sector Establishments Employment 
Output 
($000s) 
Agricultural & marine biotechnology  9   53  $4,456.8 
Pharmaceutical & diagnostic substances  123   11,089  $4,540,290.9 
Wholesale trade  108   5,973  $993,327.3 
Scientific & analytical instruments  235   23,877  $4,984,968.6 
Information & data processing  34   4,294  $616,332.7 
Medical & diagnostic labs  36   600  $34,721.3 
Research & development in life sciences  232   16,589  $1,594,512.9 
  Total  776   62,476  $12,768,610.4 
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Figure 10.  Output in Massachusetts’s biotechnology industry. 
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Figure 11.  Employment in Massachusetts’s biotechnology industry. 
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4.4 BIOTECHNOLOGY IN NEW HAMPSHIRE 
 The biotechnology industry in New Hampshire consists of 95 establishments.  These 
businesses produced $769.1 million in output, paid $203.8 million in wages and 
salaries, and employed 3,884 workers in 2002.  When multiplier effects are included, 
the industry contributed $1,193.9 million in output to the state economy, provided 
$321.0 million in personal income, and supported 8,365 jobs in New Hampshire. 
 More than one-half of the establishments in New Hampshire’s biotechnology 
industry are involved in the manufacturing of specialized measuring, medical and 
laboratory instruments.  Many of these businesses produce goods that support the 
extensive biomedical research activities taking place in Massachusetts (Rainey and 
Associates, 2002). 
 The biotechnology industry is highly concentrated in the southern part of New 
Hampshire.  This concentration reflects the strong influence of Boston’s 
biotechnology center on the development of New Hampshire’s biotechnology 
industry. 
 
Table 9.  Economic impact of the New Hampshire biotechnology industry. 
 
Direct 
impacts 
Multiplier  
effects 
Total impact 
($000s) 
    
  Output ($000s) $ 769,097.0  $ 424,839.5  $ 1,193,936.5 
    
  Income ($000s) $ 203,834.1 $ 117,125.2  $ 320,959.3 
    
  Employment   3,884   4,481  8,365 
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Table 10.  Sub-sector employment and output in New Hampshire’s biotechnology 
industry. 
          Industry Sub-sector Establishments Employment 
Output 
($000s) 
Agricultural & marine biotechnology * * * 
Pharmaceutical & diagnostic substances  16   511   $177,003.1  
Wholesale trade * * * 
Scientific & analytical instruments  50   2,895   $547,684.8 
Information & data processing * * * 
Medical & diagnostic labs  5   69   $3,663.5  
Research & development in life sciences  15   258   $20,209.4  
  Total  95   3,884   $769,097.0  
*Data withheld; category includes 3 or fewer establishments. 
 
  
Figure 12.  Output in New Hampshire’s biotechnology industry. 
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Figure 13.  Employment in New Hampshire’s biotechnology industry. 
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4.5 BIOTECHNOLOGY IN RHODE ISLAND 
 The biotechnology industry in Rhode Island consists of 32 establishments.  These 
businesses produced $240.2 million in output, paid $53.0 million in wages and 
salaries, and employed 1,152 workers in 2002.  When multiplier effects are included, 
the industry contributed $278.0 million in output to the Connecticut economy, 
provided $85.7 million in personal income, and supported 2,094 jobs. 
 Rhode Island’s biotechnology industry is heavily dominated by establishments that 
manufacture specialized measuring, medical and laboratory instruments. 
 The biotechnology industry in Rhode Island is among the smallest of the New 
England states.  While Rhode Island has more than twice as many biotechnology 
businesses as Vermont, the two states are roughly similar in terms of biotechnology-
related employment and output. 
 
Table 11.  Economic impact of the Rhode Island biotechnology industry. 
 
Direct 
impacts 
Multiplier  
effects Total impact 
    
  Output ($000s) $  240,212.3  $ 37,764.8 $  277,977.1 
    
  Income ($000s) $   52,991.4 $  32,702.6 $  85,694.0 
    
  Employment 1,152 942 2,094 
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Table 12.  Sub-sector employment and output in Rhode Island’s biotechnology 
industry. 
          Industry Sub-sector Establishments Employment 
Output 
($000s) 
Agricultural & marine biotechnology * * * 
Pharmaceutical & diagnostic substances * * * 
Wholesale trade  8   99   $ 22,464.5  
Scientific & analytical instruments  9   792   $ 156,810.9  
Information & data processing * * * 
Medical & diagnostic labs * * * 
Research & development in life sciences  8   119  $ 24,615.5  
  Total  32   1,152  $ 240,212.3  
*Data withheld; category includes 3 or fewer establishments. 
 
Figure 14.  Output in Rhode Island’s biotechnology industry. 
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Figure 15.  Employment in Rhode Island’s biotechnology industry. 
  Measuring, medical & lab 
instruments
68.8%
  R&D in life sciences
10.3%
  Wholesale trade
8.6%
  Other
12.3%
 33 
4.6 BIOTECHNOLOGY IN VERMONT 
 Vermont’s biotechnology industry consists of 14 establishments.  These businesses 
produced $236.2 million in output, paid $58.4 million in wages and salaries, and 
employed 1,337 workers in 2002.  When multiplier effects are included, the industry 
contributed $362.0 million in output to the Vermont economy, provided $103.8 
million in personal income, and supported 2,889 jobs. 
 The biotechnology industry in Vermont is heavily dominated by establishments that 
manufacture specialized measuring, medical and laboratory instruments.  No other 
sub-sector has more than three establishments. 
 Vermont’s biotechnology industry is among the smallest of the New England states.  
It has the fewest establishments, lowest output, and second-lowest number of 
workers. 
 
Table 13.  Economic impact of the Vermont biotechnology industry. 
 
Direct 
impacts 
Multiplier  
effects 
Total impact 
($000s) 
    
  Output ($000s) $  236,179.2  $ 125,830.4 $ 362,009.6 
    
  Income ($000s) $  58,363.4 $  45,445.3 $  103,808.7 
    
  Employment    1,337   1,552 2,889 
 
 34 
Table 14.  Sub-sector employment and output in Vermont’s biotechnology industry. 
          Industry Sub-sector Establishments Employment 
Output 
($000s) 
Agricultural & marine biotechnology * * * 
Pharmaceutical & diagnostic substances * * * 
Wholesale trade * * * 
Scientific & analytical instruments 8  941   $161,526.8  
Information & data processing * * * 
Medical & diagnostic labs * * * 
Research & development in life sciences * * * 
  Total  14   1,337   $236,179,226  
*Data withheld; category includes 3 or fewer establishments. 
 
 Figure 16.  Output in Vermont’s biotechnology industry. 
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 Figure 17.  Employment in Vermont’s biotechnology industry. 
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6. APPENDIX: BIOTECHNOLOGY INDUSTRY DEFINITIONS 
 
In their broadest application, several of the industry categories (e.g., wholesale trade) used 
in this study encompass biotechnology and non-biotechnology establishments.  To avoid 
overestimating the amount of economic activity associated with the biotechnology industry, 
the study includes only those establishments that appear in the biotechnology business 
directories. 
 
 Agricultural & marine biotechnology:  Based on technologies designed to create 
improved plant and animal products and byproducts by utilizing or engineering 
biologically derived products and marine microorganisms.  Applications include: 
improved methods of aquaculture and fisheries production; genetically modified 
foods; technologies for early detection of environmental pathogens and health 
hazards; development of biopesticides; novel approaches for environmental cleanup 
and restoration; development of new, marine-based compounds (such as 
pharmaceuticals and nutraceuticals); and industrial applications for microbial 
products. 
 
 Pharmaceutical & diagnostic substances:  Development and manufacture human 
and animal pharmaceutical and diagnostic products.  Category includes diagnostics 
(biosensors, gene tagging, polymerase chain reaction amplification, diagnostic test 
products), therapeutics (vaccines, gene therapy, immune stimulants, 
biopharmaceuticals), and drug delivery systems. 
 
 Wholesale trade:  Includes establishments that are involved primarily in the 
wholesale supply and repackaging of specialized products for the biotechnology 
industry, such as antigens, antibodies, chemical preparations and reagents.   
 
 Scientific & analytical instruments:  Includes establishments that manufacture 
specialized laboratory equipment utilized by the biotechnology industry, such as 
process, monitoring, measuring and control devices, and consumable supplies.  
Specific examples include bioreactors, DNA sequencers, cytometers, and assay 
equipment. 
 
 Information & data processing:  Refers specifically to firms engaged in the field of 
bioinformatics – the creation, maintenance and processing of biological information.  
Establishments in this category conduct research and provide services that apply the 
analytic theory and practical tools of mathematics and computer science to 
development and analysis of systematic biological data (e.g. genomes). 
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 Medical & diagnostic labs:  Stand-alone laboratories that provide diagnostic and 
analytical services for the biotechnology industry.   
 
 Research and development in life sciences:  Includes non-profit and commercial 
establishments that are engaged primarily in conducting research and development in 
biotechnology and related life sciences.  Examples of research fields include 
genetics, genomics, proteomics, biosensors, and materials-microbe interactions. 
 
